| HS Code | 250968 |
| Grade | Polymer grade |
| Chemical Name | 2-Ethylhexyl Acrylate (with MEHQ inhibitor) |
| Cas Number | 103-11-7 |
| Molecular Formula | C11H20O2 |
| Molecular Weight | 184.28 g/mol |
| Appearance | Clear, colorless liquid |
| Purity | ≥99.5% |
| Mehq Inhibitor Content | 10–15 ppm |
| Water Content | ≤0.05% |
| Acidity As Acrylic Acid | ≤0.01% |
| Color Apha | ≤20 |
| Specific Gravity 20 20 C | 0.881–0.885 |
| Boiling Point | 215–219 °C |
| Melting Freezing Point | -90 °C |
| Flash Point Closed Cup | 84 °C |
| Refractive Index 20 C | 1.4360–1.4370 |
| Solubility In Water | Slightly soluble (0.04 g/100 mL at 20 °C) |
| Viscosity 20 C | 1.2 mPa·s |
As an accredited Polymer Grade MEHQ 10–15 ppm (Medical / Children's Products Adhesive) factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in 25 kg HDPE drums with nitrogen purge, sealed to maintain 10–15 ppm MEHQ purity for medical adhesive use. |
| Container Loading (20′ FCL) | 20′ FCL loading of Polymer Grade MEHQ (10–15 ppm) for medical/children's adhesives: secure packing, proper labeling, and careful handling. |
| Shipping | Ship as a non-hazardous, polymer-grade adhesive containing MEHQ at 10–15 ppm, suitable for medical/children’s products. Pack in sealed, leak-proof containers with clear labels and SDS. Store cool and dry, away from heat, sparks, and direct sunlight. Handle with standard PPE to prevent skin or eye contact. |
| Storage | Store in tightly sealed, original containers in a cool, dry, well-ventilated area away from direct sunlight, heat, sparks, and open flames. Maintain temperatures between 15–25°C. Keep away from incompatible materials and oxidizers. Ensure containers remain closed when not in use to preserve inhibitor efficacy and prevent contamination or polymerization. |
| Shelf Life | Stable for 12 months when stored sealed, cool, dry, and away from light; avoid excessive heat or contamination. |
Photopolymerized acrylic pressure-sensitive adhesives for transparent wound dressings and surgical incise drapes are compounded from 2-ethylhexyl acrylate, n-butyl acrylate, and acrylic acid feeds stabilized with MEHQ at 10–15 ppm. The MEHQ inhibitor is not a post-added excipient but an inherent monomer-feed variable that carries into the UV syrup polymerization step. On production lines built around a 1,200 mm slot-die coater with closed-loop gravimetric monomer metering and medium-pressure mercury arc lamps, the shift from 10 ppm to 15 ppm MEHQ measurably extends the induction period and reduces the gel fraction of the syrup at fixed UV energy, because MEHQ scavenges photoinitiator-derived radicals in competition with chain propagation. Coating is performed at 20–45 g/m² onto release-coated polyester or paper liner and laminated to 25–50 µm polyurethane or polyethylene film, followed by rotary die-cutting at 80–140 m/min. Industry compliance is anchored to ISO 10993-5:2009 for cytotoxicity, ISO 10993-10:2010 for sensitization and irritation, and ISO 10993-23:2021 for in vitro skin irritation of the finished adhesive article; device-level biological evaluation follows ISO 10993-1:2018. Terminal products include transparent film dressings, island wound dressings, surgical incise drapes with acrylic adhesive margins, and reinforcing strips for sterile drape adhesion. Operational boundary: MEHQ inhibition efficiency is oxygen-dependent; monomer storage under nitrogen with less than 0.5 vol% oxygen should not exceed 30 days without supplementary inhibitor validation.
In solvent-based acrylic PSA coating for neonatal ECG electrodes and pulse-oximetry wraps, the monomer phase—typically 55–65 wt% solids before polymerization—is stabilized with MEHQ at 10–15 ppm and polymerized in ethyl acetate at 78–82 °C using azo initiators. The residual MEHQ consumes initiator-derived radicals during the induction period; at the upper end of 15 ppm, the resulting number-average molecular weight falls and the gel content decreases when compared with the 10 ppm condition under identical reactor time and temperature. This shift is observed as lower shear-holding force in ASTM D3654/D3654M-06 testing and a softer peel plateau in ASTM D3330/D3330M-04 Procedure A. The coating process uses a closed-circuit slot-die coater with a 1,000 mm width, three-zone forced-air oven drying at 60–110 °C, and in-line corona treatment of the 20–40 µm TPU or nonwoven facestock to 38–42 dyn/cm. Compliance includes ISO 10993-1:2018 biological evaluation, ISO 10993-5:2009 cytotoxicity, and ISO 10993-23:2021 skin irritation; the finished neonatal electrode adhesive must also pass AAMI/ANSI EC12 or equivalent electrode performance requirements where applicable. Terminal products include neonatal ECG electrodes, infant pulse-oximeter sensor wraps, and single-patient-use temperature probe covers. Published comparative line data for the exact 10–15 ppm band in neonatal electrode coating is limited; however, the gel-fraction directionality is consistent with inhibitor kinetics observed in comparable acrylic syrup systems.
| Application segment | Primary compliance standard | Test method | MEHQ-related boundary |
|---|---|---|---|
| Wound-care acrylic PSA | ISO 10993-5:2009 | L929 MEM elution | monomer feed 10–15 ppm |
| Neonatal electrode PSA | ISO 10993-23:2021 | Reconstructed human epidermis irritation | residual free MEHQ <5 ppm |
| Transdermal drug-in-adhesive | ISO 10993-10:2010 | Skin sensitization | residual inhibitor controlled by drying |
| Paediatric device UV adhesive | ISO 10993-5:2009 | L929 MEM elution | cured network 50–150 µm |
| Children’s toy structural bond | EN 71-3:2019+A1:2021 | Element migration | cured bondline |
| Ostomy hydrocolloid barrier | ISO 10993-10:2010 and ISO 10993-23:2021 | 24 h skin patch | residual phenolic <15 ppm |
Drug-in-adhesive transdermal patch manufacturing introduces an additional constraint because the MEHQ inhibitor concentration in the acrylate copolymer phase can affect residual peroxide decomposition and drug-excipient stability. Acrylate syrup for transdermal adhesives is typically prepared from 2-ethylhexyl acrylate, methyl acrylate, and acrylic acid with MEHQ at 10–15 ppm of monomer, then compounded with the active pharmaceutical ingredient at 1–10 wt% and coated at 30–80 g/m² onto fluoropolymer release liner. The coating line uses a precision comma-bar or slot-die coater at 0.5–4.0 m/min with three-zone forced-air drying at 50–95 °C; residual solvent is controlled to ICH Q3C limits for the selected solvent class. Compliance for the adhesive portion includes ISO 10993-5:2009, ISO 10993-10:2010, and ISO 10993-23:2021, while the finished transdermal product is subject to pharmacopoeial drug release testing and the relevant national regulatory submission. Terminal product types include nicotine, fentanyl, lidocaine, and estradiol transdermal patches; estradiol hemihydrate systems in particular require tight control of residual monomer and inhibitor because both can migrate into the drug reservoir and alter crystal habit. Operational boundary: avoid combination with alkaline or amine-functional monomers in the pre-coated syrup, as these species can consume MEHQ and create localized radical polymerization exotherms before the coating die. Published data for this specific configuration is limited, so residual MEHQ and drug-release interaction should be verified in the final formulation.
UV-curable acrylic structural adhesives used for bonding polycarbonate, ABS, and flexible PVC components in paediatric respiratory circuits and enteral feeding sets are formulated from methacrylate monomers stabilized with MEHQ at 10–15 ppm. The inhibitor concentration controls open-time stability before photoinitiation; at 15 ppm, pot life under ambient production lighting extends to 8–10 min, while at 10 ppm premature auto-polymerisation is more likely if the adhesive is left in unshielded dispensing reservoirs. The formulation contains 70–85 wt% methyl methacrylate, 15–25 wt% methacrylate ester flexibiliser, and 1–3 wt% photoinitiator; MEHQ is introduced as part of the monomer feed and is not independently adjusted after compounding. Curing is carried out on a conveyorised 395 nm UV LED line with peak irradiance of 1,500–2,500 mW/cm², producing a bondline thickness of 50–150 µm and full fixture in 2.5–5.0 s. Post-cure inspection under 365 nm black light detects uncured monomer pools in shadowed joints, which can occur in low-clearance polycarbonate connectors when MEHQ is at the upper 15 ppm end and cure depth drops by 10–20%. Compliance includes ISO 10993-1:2018 biological evaluation, ISO 10993-5:2009 cytotoxicity, ISO 10993-10:2010 sensitization, and FDA 21 CFR 177.2600 where elastomeric components are intended for repeated contact in medical devices. Terminal products include paediatric nebulizer housings, bite blocks, enteral feeding connectors, and needle-free IV access caps.
| Application segment | MEHQ addition ratio | Downstream production process | Terminal product types |
|---|---|---|---|
| Wound-care acrylic PSA | 10–15 ppm in monomer feed | UV syrup polymerization, slot-die coating at 20–45 g/m² | Transparent film dressings, incise drapes |
| Neonatal electrode PSA | 10–15 ppm in monomer phase | Solvent polymerization, slot-die coating, forced-air drying at 60–110 °C | Neonatal ECG electrodes, pulse-oximetry wraps |
| Transdermal drug-in-adhesive | 10–15 ppm of monomer | Precision comma-bar coating at 30–80 g/m², multi-zone drying | Nicotine, fentanyl, lidocaine, estradiol patches |
| Paediatric device UV adhesive | 10–15 ppm of methacrylate feed | Volumetric dispensing, 395 nm LED cure | Respiratory circuit components, enteral connectors |
| Children’s toy structural bond | 10–15 ppm in methacrylate monomer | Plasma pre-treatment, jet dispensing, 395 nm LED line | Toy housings, baby monitors, storage cases |
| Ostomy hydrocolloid barrier | 10–15 ppm in acrylate phase | Twin-screw compounding at 120–170 °C, thick-film coating | Ostomy barriers, wound pouching, continence strips |
Assembly of children’s toys and childcare articles made from polycarbonate, ABS, and PMMA requires that the cured adhesive does not release heavy metals, plasticizers, or other restricted substances above the relevant migration limits. The methacrylate monomer feed for these UV-curing structural adhesives is stabilised with MEHQ at 10–15 ppm; the cured network typically retains less than 5 ppm free MEHQ, and the compound does not introduce heavy-metal or phthalate migration risk when evaluated under EN 71-3:2019+A1:2021, CPSIA Section 108, and 16 CFR 1307. The formulation includes 60–78 wt% methyl methacrylate, 10–25 wt% 2-ethylhexyl methacrylate, 5–12 wt% acidic adhesion-promoting methacrylate, and 0.5–2.0 wt% photoinitiator. Production uses precision volumetric jet dispensers to apply 0.01–0.05 mL per bond point, followed by a conveyorised 395 nm LED line running at 10–18 m/min; polyolefin substrates require in-line plasma treatment to 42–46 dyn/cm before bonding. Terminal product types include transparent toy housings, baby monitor enclosures, childcare activity centre trays, and child-safe storage cases with snap-fit adhesive backup. Operational limitation: avoid solvent wiping with acetone or methyl ethyl ketone before UV cure, as solvent residue can dilute the adhesive and reduce the inhibition threshold from residual MEHQ, leading to uncured surface tack.
Hydrocolloid ostomy and continence care skin barriers are formulated from a continuous phase of styrene-isoprene-styrene and polyisobutylene or, in higher-cohesion acrylate-modified grades, an acrylic phase polymerized from 2-ethylhexyl acrylate, methyl acrylate, and acrylic acid with MEHQ at 10–15 ppm. The acrylic phase is produced by UV or solvent polymerization, then compounded with sodium carboxymethyl cellulose, gelatin, and pectin at 20–35 wt% solids in a co-rotating twin-screw extruder with L/D 40:1 at barrel temperatures of 120–170 °C. The compounded mass is coated at 1.0–2.5 mm thickness onto polyurethane film or hydrocolloid-compatible nonwoven and die-cut to body-contour shapes. MEHQ in the acrylate feed must remain at or below 15 ppm because higher residual phenolic inhibitor can migrate to the adhesive–skin interface and contribute to cumulative skin sensitization potential; compliance therefore requires ISO 10993-10:2010, ISO 10993-23:2021, and ISO 10993-5:2009, with additional extractables testing according to ISO 10993-18:2020 where the finished barrier is marketed as a long-term skin-contact medical device. Terminal product types include one-piece and two-piece ostomy barriers, wound pouching systems, and infant continence pad adhesive strips. Given the long skin-contact duration, the formulation should not be combined with amine-based hydrocolloid additives that accelerate MEHQ oxidation to coloured quinone species, as this can change adhesive colour and increase potential skin-sensitizing extractables.
Competitive Polymer Grade MEHQ 10–15 ppm (Medical / Children's Products Adhesive) prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615380400285 or mail to sales2@liwei-chem.com.
We will respond to you as soon as possible.
Tel: +8615380400285
Email: sales2@liwei-chem.com
Flexible payment, competitive price, premium service - Inquire now!
In low-residual acrylic adhesive systems intended for medical device subassembly and children’s articles, the mono methyl ether of hydroquinone (MEHQ, CAS 150-76-5) is retained at 10–15 ppm in the polymerizable matrix. Polymer Grade MEHQ 10–15 ppm (Medical / Children’s Products Adhesive) is supplied as a solvent-free acrylic adhesive base with inhibitor concentration certified by reverse-phase high-performance liquid chromatography. The additive does not function as a plasticizer or adhesion promoter; it operates as a free-radical scavenger during shipping, storage, and pre-cure hold periods, preventing premature propagation and gelation while allowing faster cure initiation than grades stabilized at 50–200 ppm. The concentration window is intended for converters who require reduced phenolic carryover in finished bonds and who manage bulk thermal exposure within defined limits.
The inhibitor mechanism is aerobic and sacrificial: MEHQ donates a hydrogen atom to a peroxy radical, generating a less reactive phenoxy radical and interrupting autoxidation. Under anaerobic conditions, MEHQ is less effective because peroxy radical generation is minimized; under aerobic conditions, inhibitor consumption is continuous. At 10–15 ppm, the molar burden of MEHQ is approximately 0.08–0.12 mmol/kg of polymerizable matrix, compared with 0.40–1.61 mmol/kg for 50–200 ppm general-purpose loadings. This molar difference is substantial enough to shift induction time in ultraviolet-cure processes but is not a practical substitute for oxygen exclusion at the substrate surface.
Radical chain length in free-radical photopolymerization is governed by the ratio of propagation to termination events; MEHQ does not simply delay the onset of polymerization but also lowers the steady-state radical population until the inhibitor is consumed. In a low-inhibitor acrylic adhesive, the induction period is shorter, and the surface layer reaches gel point more rapidly under sealed or nitrogen-inerted conditions. However, in open-air coating, oxygen remains the dominant surface inhibitor. Therefore, the benefit of 10–15 ppm MEHQ is not a substitute for nitrogen inerting or high-intensity 365–405 nm LED exposure. It reduces the additional lag contributed by phenolic scavenger, allowing line-speed increases only when the oxygen diffusion boundary layer is controlled.
For comparative evaluation, the dose-to-gel point can be measured by differential scanning calorimetry according to ISO 11357-1, with a photocalorimetric accessory. Thermal reaction onset and exotherm behavior are assessed per ISO 11357-5:2013. Mechanical performance of bonded assemblies is evaluated by lap-shear testing per ISO 4587:2003, with bond-line thickness controlled to 0.10 mm using glass bead spacers. Because the lower inhibitor level shifts the arrest of surface conversion, converters should monitor surface tack after ultraviolet LED exposure rather than assume bulk conversion from single-pass Fourier transform infrared spectroscopy.
On production-scale slot-die coating lines equipped with 385 nm LED arrays operating at irradiance up to 12 W/cm², the lower inhibitor concentration reduces the exposure window required to reach a tack-free surface. The general relationship between phenolic inhibitor concentration and acrylate photopolymerization response is documented in public literature, but published data for this specific configuration is limited. The critical process conflict is not final conversion but thermal stability during hold time. Jacketed reservoirs should remain at 20–25 °C; recirculation loops with dead zones must be avoided because stagnant low-inhibitor acrylic can develop gel seeds at 35 °C over extended hold times. Batch-to-batch inhibitor variance is controlled by mass-flow dosing of MEHQ into the monomer stream and verified by HPLC; within-lot variability below ±2 ppm is achievable but should be checked against the certificate of analysis for each lot.
Viscosity control is a useful early indicator of unintended polymerization. When measured with a rotational viscometer at defined shear rate according to ISO 3219-1:2021, viscosity drift greater than ±10% within 24 h at 25 °C may indicate premature molecular-weight growth and should trigger inhibitor depletion testing. The processing window between sluggish cure and premature polymerization is narrower than in higher-inhibitor grades, so viscosity and temperature excursions cannot be managed with the same tolerances used for general-purpose adhesives.
Compared with hydroquinone, MEHQ has only one free hydroxyl group; this reduces the formation of quinoid chromophores in alkaline or oxidizing environments and lowers water sensitivity of the phenolic residue. Compared with 50–200 ppm MEHQ industrial grades, the 10–15 ppm grade gives faster cure onset but reduced bulk storage stability. Compared with zero-inhibitor acrylics, the 10–15 ppm MEHQ grade provides a defined stabilization margin for controlled storage, yet it retains enough sensitivity that nitrogen-blanketed tanks, heated transfer lines, and long residence-time mixers require detailed thermal mapping before introduction.
The finished adhesive’s suitability for children’s articles is not established by the raw material grade alone. The lower MEHQ concentration reduces the total phenolic pool available for migration, but migration testing is required with the specific substrate, adhesive coat weight, and cure profile. For toys and childcare articles sold in the European Union, the relevant chemical limits include EN 71-3:2019+A1:2021 for migration of certain elements and the general safety requirements of Directive 2009/48/EC. In the United States, the applicable framework includes CPSIA Section 108 for restricted phthalates, where each restricted phthalate is limited to 0.1% by weight of accessible component, and lead content in surface coatings under 16 CFR 1303, with the lead limit at 90 ppm.
For any food-contact use, the adhesive must satisfy FDA 21 CFR 175.105 or 175.125 if the adhesive is a pressure-sensitive adhesive, with extraction testing matched to the food simulant and temperature of use. FDA 21 CFR 175.105 has been applied with a migration threshold of 50 ppb for each adhesive component in the absence of a functional barrier. Medical devices require a documented biological evaluation plan under ISO 10993-1. Cytotoxicity per ISO 10993-5:2009, sensitization per ISO 10993-10:2021, and irritation per ISO 10993-23:2021 are commonly required for skin-contacting adhesive housings. The raw adhesive is not inherently biocompatible; the final cured combination with substrate, coating weight, and post-cure must be tested.
Extractable migration from cured acrylic networks follows Fickian concentration-gradient kinetics; low initial MEHQ reduces the reservoir of free phenolic but does not alter the diffusivity of residual monomer. The effective diffusion coefficient is governed by crosslink density, free volume, and temperature. For this reason, a 10–15 ppm inhibitor level is not a migration conclusion but a formulation boundary that must be paired with high conversion and low residual monomer. Extract preparation should follow ISO 10993-12 for medical devices or the appropriate food-contact extraction protocol defined in FDA 21 CFR 175.105 or EU 10/2011.
Storage of a low-inhibitor acrylic system below 25 °C is mandatory unless continuous dissolved oxygen sparging is present. Nitrogen blanketing reduces oxygen partial pressure and decreases inhibitor regeneration; in 10–15 ppm MEHQ formulations, prolonged nitrogen blanketing without chilling can accelerate consumption of the inhibitor and raise the risk of heterogeneous gel formation. Bulk storage tanks should be constructed of 316L stainless steel or high-density polyethylene, with no copper, brass, or iron fittings because transition-metal ions can decompose hydroperoxides and initiate redox decomposition. The recommended maximum hold temperature for drum-off in a low-inhibitor acrylic adhesive is 30 °C; excursions above 35 °C require a documented thermal history and re-test for inhibitor content and viscosity before use. Combination with amine-based redox accelerators requires explicit gel-time validation because tertiary amines can alter inhibitor depletion rate and shorten pot life.
The product is differentiated from general-purpose acrylic adhesives principally by the controlled inhibitor loading and the resulting thermal sensitivity. The following comparative matrix summarizes stabilizer regimes and operational boundaries.
| Stabilizer system | Typical residual level | Cure onset relative to this grade | Storage boundary | Main application |
|---|---|---|---|---|
| MEHQ, polymer grade | 10–15 ppm | faster onset | ≤30 °C drum-off | medical and children’s product adhesives |
| MEHQ, general purpose | 50–200 ppm | slower onset | ambient bulk storage | general industrial lamination |
| Hydroquinone | 25–100 ppm | slower onset and greater quinoid discoloration risk | ambient bulk storage | lower-cost acrylic systems |
| No added inhibitor | 0 ppm | fastest onset but unstable in storage | nitrogen/chilled | laboratory-scale photocuring only |
Compliance for the finished medical device or children’s article must be established on the final assembly, not on the liquid adhesive alone. The following matrix lists the principal standards and regulations applied to bonded medical and children’s product applications.
| Standard / regulation | Focus | Application condition |
|---|---|---|
| ISO 10993-5:2009 | cytotoxicity | extract dilution testing on finished adhesive/substrate assembly |
| ISO 10993-10:2021 | skin sensitization | required for prolonged skin-contact wearable devices |
| ISO 10993-23:2021 | irritation | required for skin-contact devices |
| EN 71-3:2019+A1:2021 | migration of certain elements | toys and childcare articles |
| FDA 21 CFR 175.105 | indirect food additive, adhesives | extraction testing under intended conditions |
| EU 10/2011 | plastic layers in food contact | overall migration limit 10 mg/dm² where the adhesive forms a plastic layer |
| 16 CFR 1303 | lead in surface coatings | lead content 90 ppm in surface coating of children’s products |
| CPSIA Section 108 | restricted phthalates | each restricted phthalate 0.1% in accessible component |
Unless the adhesive is fully crosslinked and post-cured, residual monomer and low-molecular-weight oligomers can migrate into skin-contact layers. The 10–15 ppm MEHQ grade does not eliminate the need for post-cure conversion measurement by Fourier transform infrared spectroscopy or gas chromatography. Manufacturers should establish a correlation between ultraviolet dose, conversion, and extractables before process lock for medical devices or children’s products.